Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06106581 | A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years | PHASE2 | COMPLETED | 304 | — | — | Dec 18, 2023 | Jul 2, 2025 | Aug 8, 2025 | 3 | Dominican Republic, Honduras |
| Arm | Type | Description |
|---|---|---|
| VLA1553 full dose | EXPERIMENTAL | - |
| VLA1553 half dose | EXPERIMENTAL | - |
| Control | ACTIVE_COMPARATOR | Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization |
| Name | Type | Description |
|---|---|---|
| VLA1553 full dose | BIOLOGICAL | Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate |
| VLA1553 half dose | BIOLOGICAL | Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate |
| Control | BIOLOGICAL | Nimenrix |
Inclusion Criteria: 1. Male or female healthy children aged 7 to 11 years for Stratum A, 3 to 6 years for Stratum B and 1 to 2 years for Stratum C at the time of vaccination; 2. Written informed consent by the participant's parent(s)/Legally Acceptable Representative(s) ((LAR(s)), according to loca...